179034-99-2

Upstream product

• 75890-68-5 [2-(formylamino)-1,3-thiazol-4-yl]acetic acid 
• 179034-64-1 benzhydryl 7β-(2-phenylacetamido)-3-(5-methyl-1,3,4-thiadiazol-2-yl)thio-3-cephem-4-carboxylate 
• 92096-37-2 benzhydryl (6R,7R)-7β-[(phenylacetyl)amino]-3-[(methylsulfonyl)oxy]-3-cephem-4-carboxylate 
• 54639-48-4 (6R,7R)-benzhydryl 3-hydroxy-8-oxo-7-(2-phenylacetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
• 782441-52-5 [2-(formylamino)-1,3-thiazol-4-yl]acetyl chloride 

Downstream Products

• 179035-00-8 benzhydryl 7β-[2-(2-aminothiazol-4-yl)acetamido]-3-(5-methyl-1,3,4-thiadiazol-2-yl)thio-3-cephem-4-carboxylate 

Relevant academic research and scientific papers

studies on anti-helicobacter pylori agents. Part 2: New cephem derivatives

The synthesis and optimization of the anti-Helicobacter pylori activity of a novel series of cephem derivatives are described. Introduction of thio-heterocyclic groups containing N- and S-atoms to the 3-position and phenyl or thienyl acetamido groups to the 7-position of the cephem nucleus dramatically improved the activity. From this series of derivatives, compound 13i was found to have extremely potent in vitro anti-H. pylori activity, superior therapeutic efficacy compared to AMPC and CAM, no cross-resistance between CAM or MNZ and low potential for causing diarrhea due to instability to β-lactamase. Copyright (C) 2000 Elsevier Science Ltd.